CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells

被引:6
|
作者
Wu, Wenjing [1 ,2 ]
Zhao, Jianli [1 ,2 ]
Xiao, Jianhong [3 ]
Wu, Weijun [1 ,4 ]
Xie, Limin [1 ]
Xie, Xiaojuan [1 ]
Yang, Chaoye [1 ]
Yin, Dong [1 ]
Hu, Kaishun [1 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Hong Kong Joint Lab RNA Med, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Breast Oncol, Guangzhou 510120, Guangdong, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Dept Hematol, Shenzhen 518000, Guangdong, Peoples R China
[4] Univ South China, Affiliated Hosp 1, Dept Radiotherapy, Hengyang 421001, Peoples R China
基金
中国国家自然科学基金;
关键词
CHFR; PARylation; PARP1; RNF126; Ubiquitination; ADP-RIBOSYLATION; HOMOLOGOUS RECOMBINATION; E3; LIGASE; PROTEIN; UBIQUITINATION; CHECKPOINT; AXIN;
D O I
10.1016/j.bbrc.2021.08.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ring-finger protein 126 (RNF126), an E3 ubiquitin ligase, plays crucial roles in various biological processes, including cell proliferation, DNA damage repair, and intracellular vesicle trafficking. Whether RNF126 is modulated by posttranslational modifications is poorly understood. Here, we show that PARP1 interacts with and poly(ADP)ribosylates RNF126, which then recruits the PAR-binding E3 ubiquitin ligase CHFR to promote ubiquitination and degradation of RNF126. Moreover, RNF126 is required for the activation of ATR-Chk1 signaling induced by either irradiation (IR) or a PARP inhibitor (PARPi), and depletion of RNF126 increases the sensitivity of triple-negative breast cancer (TNBC) cells to PARPi treatment. Our findings suggest that PARPi-mediated upregulation of RNF126 protein stability contributes to TNBC cell resistance to PARPi. Therefore, targeting the E3 ubiquitin ligase RNF126 may be a novel treatment for overcoming the resistance of TNBC cells to PARPi in clinical trials. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 50 条
  • [41] Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
    Jain, Aditi
    Barge, Alan
    Parris, Christopher N.
    ONCOGENE, 2025, 44 (04) : 193 - 207
  • [42] Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
    Moustafa, Dina
    Elwahed, Maha R. Abd
    Elsaid, Hanaa H.
    Parvin, Jeffrey D.
    PLOS ONE, 2021, 16 (01):
  • [43] Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer
    Li, Chen
    Wang, Xiaolong
    Xing, Luyao
    Chen, Tong
    Li, Wenhao
    Li, Xin
    Wang, Yifei
    Yang, Chao
    Yang, Qifeng
    PHYTOMEDICINE, 2024, 135
  • [44] Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
    Hsiao-Ching Chuang
    Naval Kapuriya
    Samuel K. Kulp
    Ching-Shih Chen
    Charles L. Shapiro
    Breast Cancer Research and Treatment, 2012, 134 : 649 - 659
  • [45] Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
    Chuang, Hsiao-Ching
    Kapuriya, Naval
    Kulp, Samuel K.
    Chen, Ching-Shih
    Shapiro, Charles L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) : 649 - 659
  • [46] Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
    Eskiler, Gamze Guney
    Ozman, Zeynep
    Haciefendi, Ayten
    Cansaran-Duman, Demet
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (05) : 1031 - 1041
  • [47] Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells
    Gamze Guney Eskiler
    Zeynep Ozman
    Ayten Haciefendi
    Demet Cansaran-Duman
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1031 - 1041
  • [48] Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors
    Stewart, Roxana M. Rodriguez
    Berry, Jameson T. L.
    Berger, Angela K.
    Yoon, Sung Bo
    Hirsch, Aspen L.
    Guberman, Jaime A.
    Patel, Nirav B.
    Tharp, Gregory K.
    Bosinger, Steven E.
    Mainou, Bernardo A.
    JOURNAL OF VIROLOGY, 2019, 93 (23)
  • [49] Synergistic inhibition of growth of triple-negative breast cancer cells by co-targeting PARP and HDAC
    Marijon, Helene
    Sun, Haibo
    de Gramont, Aimery
    Gery, Sigal
    Koeffler, H. Phillip
    CANCER RESEARCH, 2014, 74 (19)
  • [50] AMPK Pathway Activation Improves the Sensitivity of Triple-Negative Breast Cancer Cells to Adriamycin
    Chen, Tengteng
    Chen, Di
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2023, 37 (03): : 1597 - 1605